SAN FRANCISCO – Exuberance over China's ascendant biopharma sector formed a near-deafening roar at the 6th Annual Wuxi Global Forum last week, where Ruyi He, chief scientist of the CFDA's Center for Drug Evaluation (CDE), spoke to the accelerating pace of the Republic's regulatory reform. In the past few years, he said, not only has the agency embraced a growing body of guidelines from its regulatory agency peers but has also gone on a hiring spree aimed at boosting efficiency at the agency, which has labored under criticism in past years. Having jumped from 600 CDE reviewers to 800 in just the last year, he said that the agency is now aiming to reach a total of 1,600 reviewers by 2020.